NIH × Interventional × Esthesioneuroblastoma, Olfactory × Clear all Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Phase 2 Recruiting
40 enrolled
Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
Phase 2 Completed
11 enrolled 14 charts
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Phase 1 Completed
43 enrolled
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
Phase 1 Completed
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Phase 2 Completed
11 enrolled 7 charts
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1 Completed
41 enrolled
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
Phase 2 Unknown
60 enrolled
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
Phase 2 Completed
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Phase 1 Completed
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
30 enrolled
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Phase 1 Completed
39 enrolled
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
Phase 2 Completed
30 enrolled
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase 1 Completed
75 enrolled
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
Phase NA Completed
40 enrolled
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
75 enrolled
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
Phase 1/2 Completed